This inventor holds 2 USPTO granted patents and 1 published patent application and 3 EPO patents. Top assignee: Italfarmaco Spa. Active years: 2020-2022.
Company Filing History:
Years Active: 2020-2022
Title: Andrea Stevenazzi: Innovator in Antitumor Compounds
Introduction
Andrea Stevenazzi is a notable inventor based in Milan, Italy. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds with antitumor activity. With a total of 2 patents, his work focuses on innovative solutions for cancer treatment.
Latest Patents
Stevenazzi's latest patents include "Selective HDAC6 inhibitors," which relate to novel benzohydroxamic compounds exhibiting high selective inhibitory activity against the histone deacetylase 6 (HDAC6) enzyme. This invention holds promise for targeted cancer therapies. Another significant patent is for "Benzo-N-hydroxy amide compounds having antitumor activity," which describes new compounds that show significant inhibitory activity on the proliferation of tumor cells, specifically targeting cancer stem cells.
Career Highlights
Andrea Stevenazzi is associated with Italfarmaco Spa, a company known for its commitment to research and development in the pharmaceutical sector. His work at Italfarmaco has allowed him to focus on innovative drug development aimed at improving cancer treatment outcomes.
Collaborations
Stevenazzi collaborates with talented professionals in his field, including Barbara Vergani and Gianluca Fossati. Their combined expertise contributes to the advancement of research in antitumor therapies.
Conclusion
Andrea Stevenazzi's contributions to the field of pharmaceuticals, particularly in developing antitumor compounds, highlight his role as an innovator. His patents reflect a commitment to advancing cancer treatment, showcasing the importance of research in this critical area.